Xtant Medical Holdings Inc (XTNT) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.106x

Based on the latest financial reports, Xtant Medical Holdings Inc (XTNT) has a cash flow conversion efficiency ratio of 0.106x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.38 Million) by net assets ($50.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Xtant Medical Holdings Inc for the company's overall valuation and market capitalisation.

Xtant Medical Holdings Inc - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Xtant Medical Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Xtant Medical Holdings Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xtant Medical Holdings Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Xtant Medical Holdings Inc to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Atlantic International Corp. Common Stock
NASDAQ:ATLN
-0.154x
OptimumBank Holdings, Inc.
NYSE MKT:OPHC
0.052x
Northwest Copper Corp
V:NWST
-5.572x
Nice D&B Co. Ltd
KQ:130580
0.023x
VenHub Global, Inc.
NASDAQ:VHUB
0.150x
Sanko Pazarlama Ithalat Ihracat AS
IS:SANKO
0.077x
Forian Inc
NASDAQ:FORA
0.108x
Safety Shot Inc
NASDAQ:SHOT
-0.072x

Annual Cash Flow Conversion Efficiency for Xtant Medical Holdings Inc (2008–2025)

The table below shows the annual cash flow conversion efficiency of Xtant Medical Holdings Inc from 2008 to 2025. View Xtant Medical Holdings Inc (XTNT) share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $50.95 Million $12.55 Million 0.246x +188.93%
2024-12-31 $42.96 Million $-11.90 Million -0.277x -49.43%
2023-12-31 $51.35 Million $-9.52 Million -0.185x -18.55%
2022-12-31 $34.17 Million $-5.34 Million -0.156x -1199.56%
2021-12-31 $30.88 Million $439.00K 0.014x +128.22%
2020-12-31 $14.51 Million $-731.00K -0.050x -639.08%
2019-12-31 $-44.20 Million $-413.00K 0.009x +133.74%
2018-12-31 $-43.77 Million $1.21 Million -0.028x -399.22%
2017-12-31 $-58.70 Million $-543.18K 0.009x -99.55%
2016-12-31 $-7.07 Million $-14.41 Million 2.037x +298.69%
2015-12-31 $8.88 Million $-9.10 Million -1.025x -208.83%
2014-12-31 $-7.77 Million $-7.32 Million 0.942x -35.61%
2013-12-31 $-3.84 Million $-5.62 Million 1.463x +157.37%
2012-12-31 $4.23 Million $-10.79 Million -2.550x -90.53%
2011-12-31 $5.50 Million $-7.36 Million -1.338x -109.90%
2010-12-31 $-619.24K $-8.37 Million 13.520x +1825.08%
2009-12-31 $4.68 Million $-3.67 Million -0.784x -123.00%
2008-12-31 $11.34K $38.64K 3.407x --

About Xtant Medical Holdings Inc

NYSE MKT:XTNT USA Medical Devices
Market Cap
$67.23 Million
Market Cap Rank
#20845 Global
#4704 in USA
Share Price
$0.48
Change (1 day)
+2.11%
52-Week Range
$0.45 - $0.92
All Time High
$42.12
About

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validate… Read more